YILIMART - REAlease Anti-HLA-A2-FITC, human

Clone REAL314 is an antibody fragment derived from the full HLA-A2 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL314 recognizes the class I human leukocyte antigen A2 (HLA-A2). Expressed on the surface of most nucleated cells, class I molecules are heterodimeric molecules and consist of a type I integral membrane α heavy chain and a soluble β2 microglobulin protein. The extracellular region of the heavy chain further consists of three domains, one of which comprises the peptide binding groove. Antigens binding to class I molecules are 8–10 amino acids long and play an important role in recognition of virus infected and malignant cells by cytotoxic T lymphocytes (CTLs). In addition, class I molecules interact with natural killer (NK) cell receptors to modulate the activity of NK cells.

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

MHC class I HLA-A2

Technical specifications

Antigen: HLA-A2
Clone: REAL314
Isotype control: REAL Control
Alternative names of antigen: MHC class I HLA-A2
Distribution of antigen: nucleated cells
Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
Storage: Store protected from light at 2–8 °C. Do not freeze.
Available conjugates: FITC

Figure 1

Human peripheral blood cells after erythrocyte lysis were stained with REAlease Anti-HLA-A2-FITC (B) or with the corresponding REAL Control (A). REAlease Anti-HLA-A2-FITC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease Anti-HLA-A2-FITC (D). Cells were labeled with CD4 antibodies in addition and analyzed by flow cytometry using the MACSQuant

^®

Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

A:	B:

C:	D:

Selected references
1. Bjorkman, P. J. et al. (1987) Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329(6139): 506-512
2. Hewitt, E. W. et al. (2003) The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 110(2): 163-169
3. Smith, S. N. et al. (2013) Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes. J. Mol. Biol. 425(22): 4496-4507

查看数据文件查看下载

REAlease Anti-HLA-A2-FITC, human

For research use only

您浏览过的商品

Alternative names

Technical specifications

Figure 1

Selected references

相关产品